Corey Ratcliffe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Corey Ratcliffe has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Simon Sean Keller
Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, United Kingdom
6 shared publications - Anthony Guy Marson
Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK
5 shared publications - Christophe de Bézenac
Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, United Kingdom
3 shared publications Kumar Das
The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom
3 shared publications- Laura Jayne Bonnett
Department of Health Data Science, University of Liverpool, Liverpool, UK
3 shared publications - Peter Neal Taylor
CNNP Lab, Interdisciplinary Computing and Complex BioSystems Group, School of Computing, Newcastle University, Newcastle upon Tyne, United Kingdom
3 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by MIT Press in Imaging Neuroscience
- Vol. 4
Correction to: Machine learning-based reconstruction of 2D MRI for quantitative morphometry in epilepsy
[This corrects the article DOI: 10.1162/IMAG.a.997.].
- 11 June 2026
- Published by MIT Press in Imaging Neuroscience
- Vol. 4
Open AccessCorrection to: Machine learning-based reconstruction of 2D MRI for quantitative morphometry in epilepsy
[This corrects the article DOI: 10.1162/IMAG.a.997.].
- Open Access
- 10 November 2025
- Published by MIT Press in Imaging Neuroscience
- Vol. 3
Machine learning-based reconstruction of 2D MRI for quantitative morphometry in epilepsy
Structural neuroimaging analyses require “research quality” images, procured with costly MRI acquisitions. Isotropic (3D-T1) images are desirable for quantitative analyses, however, a routine compromise in the clinical setting is to acquire anisotropic (2D-T1) analogues for qualitative visual inspection. ML (machine learning-based) software have shown promise in addressing some of the limitations of 2D-T1 scans in research applications, yet their efficacy in quantitative research is generally poorly understood. Quantitative morphometric analyses have previously identified pathology-related abnormalities of the subcortical structures in idiopathic generalised epilepsy (IGE), which have been overlooked based on visual inspection. As such, IGE biomarkers present a suitable model in which to evaluate the applicability of image preprocessing methods. This study, therefore, explores subcortical structural biomarkers of IGE, first in our “silver standard” 3D-T1 scans, then in 2D-T1 scans that were either untransformed, resampled using a classical interpolation approach, or synthesised with a resolution and contrast agnostic ML model. 2D-T1 and 3D-T1 MRI scans were acquired during the same scanning session for 33 individuals with drug-sensitive IGE (age mean 32.16 ± SD = 14.20, male n = 14) and 42 individuals with drug-resistant IGE (31.76 ± 11.12, 17), all diagnosed at the Walton Centre NHS Foundation Trust Liverpool, alongside 39 age- and sex-matched healthy controls (32.32 ± 8.65, 16). The untransformed 2D-T1 scans were resampled into isotropic images using NiBabel (res-T1), and preprocessed into synthetic isotropic images using SynthSR (syn-T1). For the 3D-T1, 2D-T1, res-T1, and syn-T1 images, the recon-all command from FreeSurfer 8.0.0 was used to create parcellations of 174 anatomical regions (equivalent to the 174 regional parcellations provided as part of the DL+DiReCT pipeline), defined by the aseg and Destrieux atlases, and FSL run_first_all was used to segment subcortical surface shapes. The new ML FreeSurfer pipeline, recon-all-clinical, was also tested in the 2D-T1, 3D-T1, and res-T1 images. As a model comparison for SynthSR, the DL+DiReCT pipeline was used to provide segmentations of the 2D-T1 and res-T1 images, including estimates of regional volume and thickness. Spatial overlap and intraclass correlations between the morphometrics of the eight resulting parcellations were first determined, then subcortical surface shape abnormalities associated with IGE were identified by comparing the FSL run_first_all outputs of patients with controls. When standardised to the metrics derived from the 3D-T1 scans, cortical volume and thickness estimates trended lower for the 2D-T1, res-T1, syn-T1, and DL+DiReCT outputs, whereas subcortical volume estimates were more coherent. Dice coefficients revealed an acceptable spatial similarity between the cortices of the 3D-T1 scans and the other images overall, and was higher in the subcortical structures. Intraclass correlation coefficients were consistently lowest when metrics were computed for model-derived inputs, and estimates of thickness were less similar to the ground truth than those of volume. For the people with epilepsy, the 3D-T1 scans showed significant surface deflations across various subcortical structures when compared with those of healthy controls. Analysis of the 2D-T1 scans enabled the reliable detection of a subset of subcortical abnormalities, whereas analyses of the res-T1 and syn-T1 images were more prone to false-positive results. Resampling and ML image synthesis methods do not currently attenuate partial volume effects resulting from low through plane resolution in anisotropic MRI scans, instead quantitative analyses using 2D-T1 scans should be interpreted with caution, and researchers should consider the potential implications of preprocessing. The recon-all-clinical pipeline is promising, but requires further evaluation, especially when considered as an alternative to the classical pipeline.
- 10 November 2025
- Published by MIT Press in Imaging Neuroscience
- Vol. 3
Open AccessMachine learning-based reconstruction of 2D MRI for quantitative morphometry in epilepsy
Structural neuroimaging analyses require “research quality” images, procured with costly MRI acquisitions. Isotropic (3D-T1) images are desirable for quantitative analyses, however, a routine compromise in the clinical setting is to acquire anisotropic (2D-T1) analogues for qualitative visual inspection. ML (machine learning-based) software have shown promise in addressing some of the limitations of 2D-T1 scans in research applications, yet their efficacy in quantitative research is generally poorly understood. Quantitative morphometric analyses have previously identified pathology-related abnormalities of the subcortical structures in idiopathic generalised epilepsy (IGE), which have been overlooked based on visual inspection. As such, IGE biomarkers present a suitable model in which to evaluate the applicability of image preprocessing methods. This study, therefore, explores subcortical structural biomarkers of IGE, first in our “silver standard” 3D-T1 scans, then in 2D-T1 scans that were either untransformed, resampled using a classical interpolation approach, or synthesised with a resolution and contrast agnostic ML model. 2D-T1 and 3D-T1 MRI scans were acquired during the same scanning session for 33 individuals with drug-sensitive IGE (age mean 32.16 ± SD = 14.20, male n = 14) and 42 individuals with drug-resistant IGE (31.76 ± 11.12, 17), all diagnosed at the Walton Centre NHS Foundation Trust Liverpool, alongside 39 age- and sex-matched healthy controls (32.32 ± 8.65, 16). The untransformed 2D-T1 scans were resampled into isotropic images using NiBabel (res-T1), and preprocessed into synthetic isotropic images using SynthSR (syn-T1). For the 3D-T1, 2D-T1, res-T1, and syn-T1 images, the recon-all command from FreeSurfer 8.0.0 was used to create parcellations of 174 anatomical regions (equivalent to the 174 regional parcellations provided as part of the DL+DiReCT pipeline), defined by the aseg and Destrieux atlases, and FSL run_first_all was used to segment subcortical surface shapes. The new ML FreeSurfer pipeline, recon-all-clinical, was also tested in the 2D-T1, 3D-T1, and res-T1 images. As a model comparison for SynthSR, the DL+DiReCT pipeline was used to provide segmentations of the 2D-T1 and res-T1 images, including estimates of regional volume and thickness. Spatial overlap and intraclass correlations between the morphometrics of the eight resulting parcellations were first determined, then subcortical surface shape abnormalities associated with IGE were identified by comparing the FSL run_first_all outputs of patients with controls. When standardised to the metrics derived from the 3D-T1 scans, cortical volume and thickness estimates trended lower for the 2D-T1, res-T1, syn-T1, and DL+DiReCT outputs, whereas subcortical volume estimates were more coherent. Dice coefficients revealed an acceptable spatial similarity between the cortices of the 3D-T1 scans and the other images overall, and was higher in the subcortical structures. Intraclass correlation coefficients were consistently lowest when metrics were computed for model-derived inputs, and estimates of thickness were less similar to the ground truth than those of volume. For the people with epilepsy, the 3D-T1 scans showed significant surface deflations across various subcortical structures when compared with those of healthy controls. Analysis of the 2D-T1 scans enabled the reliable detection of a subset of subcortical abnormalities, whereas analyses of the res-T1 and syn-T1 images were more prone to false-positive results. Resampling and ML image synthesis methods do not currently attenuate partial volume effects resulting from low through plane resolution in anisotropic MRI scans, instead quantitative analyses using 2D-T1 scans should be interpreted with caution, and researchers should consider the potential implications of preprocessing. The recon-all-clinical pipeline is promising, but requires further evaluation, especially when considered as an alternative to the classical pipeline.
- Open Access
- 28 August 2024
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 14 (1) , 43
Exploring White Matter Microstructure with Symptom Severity and Outcomes Following Deep Brain Stimulation in Tremor Syndromes
Tremor and Other Hyperkinetic Movements (TOHM) [ISSN: 2160-8288], a fully open access peer-reviewed journal, publishes clinical and scientific papers on tremor and hyperkinetic movements. TOHM is indexed in PubMed and PubMed Central. In contrast to other publications focusing on disorders of hypokinesia (i.e., mainly Parkinson’s disease), TOHM emphasizes the hyperkinetic movements, giving center stage to clinical observations and research in this area. Papers on Parkinson’s disease and related disorders will be considered if they relate to the hyperkinetic features of these diseases (e.g., tremor, dystonia, dyskinesias). The average turnaround time from submission to first decision is roughly 24 days (~3.5 weeks). The average turnaround time from acceptance to publication is 18 days (~2.5 weeks) with a median of 14 days (2 weeks). Tremor and Other Hyperkinetic Movements is indexed with the Web of Science Emerging Sources Citation Index. As of 2024, Tremor has a Journal Impact Factor of 2.5.
- 28 August 2024
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 14 (1) , 43
Open AccessExploring White Matter Microstructure with Symptom Severity and Outcomes Following Deep Brain Stimulation in Tremor Syndromes
Tremor and Other Hyperkinetic Movements (TOHM) [ISSN: 2160-8288], a fully open access peer-reviewed journal, publishes clinical and scientific papers on tremor and hyperkinetic movements. TOHM is indexed in PubMed and PubMed Central. In contrast to other publications focusing on disorders of hypokinesia (i.e., mainly Parkinson’s disease), TOHM emphasizes the hyperkinetic movements, giving center stage to clinical observations and research in this area. Papers on Parkinson’s disease and related disorders will be considered if they relate to the hyperkinetic features of these diseases (e.g., tremor, dystonia, dyskinesias). The average turnaround time from submission to first decision is roughly 24 days (~3.5 weeks). The average turnaround time from acceptance to publication is 18 days (~2.5 weeks) with a median of 14 days (2 weeks). Tremor and Other Hyperkinetic Movements is indexed with the Web of Science Emerging Sources Citation Index. As of 2024, Tremor has a Journal Impact Factor of 2.5.
- Open Access
Machine Learning-Based Reconstruction of 2D MRI for Quantitative Morphometry in Epilepsy
Introduction: Structural neuroimaging analyses require ‘research quality’ images, acquired with costly MRI acquisitions. Isotropic (3D-T1) images are desirable for quantitative analyses, however a routine compromise in the clinical setting is to acquire anisotropic (2D-T1) analogues for qualitative visual inspection. ML (Machine learning-based) software have shown promise in addressing some of the limitations of 2D-T1 scans in research applications, yet their efficacy in quantitative research is generally poorly understood. Pathology-related abnormalities of the subcortical structures have previously been identified in idiopathic generalised epilepsy (IGE), which have been overlooked based on visual inspection, through the use of quantitative morphometric analyses. As such, IGE biomarkers present a suitable model in which to evaluate the applicability of image preprocessing methods. This study therefore explores subcortical structural biomarkers of IGE, first in our ‘silver standard’ 3D-T1 scans, then in 2D-T1 scans that were either untransformed, resampled using a classical interpolation approach, or synthesised with a resolution and contrast agnostic ML model (the latter of which is compared to a separate model). Methods: 2D-T1 and 3D-T1 MRI scans were acquired during the same scanning session for 33 individuals with drug-responsive IGE (age mean 32.16 ± SD = 14.20, male n = 14) and 42 individuals with drug-resistant IGE (31.76 ± 11.12, 17), all diagnosed at the Walton Centre NHS Foundation Trust Liverpool, alongside 39 age- and sex-matched healthy controls (32.32 ± 8.65, 16). The untransformed 2D-T1 scans were resampled into isotropic images using NiBabel (res-T1), and preprocessed into synthetic isotropic images using SynthSR (syn-T1). For the 3D-T1, 2D-T1, res-T1, and syn-T1 images, the recon-all command from FreeSurfer 8.0.0 was used to create parcellations of 174 anatomical regions (equivalent to the 174 regional parcellations provided as part of the DL+DiReCT pipeline), defined by the aseg and Destrieux atlases, and FSL run_first_all was used to segment subcortical surface shapes. The new ML FreeSurfer pipeline, recon-all-clinical , was also tested in the 2D-T1, 3D-T1, and res-T1 images. As a model comparison for SynthSR, the DL+DiReCT pipeline was used to provide segmentations of the 2D-T1 and res-T1 images, including estimates of regional volume and thickness. Spatial overlap and intraclass correlations between the morphometrics of the eight resulting parcellations were first determined, then subcortical surface shape abnormalities associated with IGE were identified by comparing the FSL run_first_all outputs of patients with controls. Results: When standardised to the metrics derived from the 3D-T1 scans, cortical volume and thickness estimates trended lower for the 2D-T1, res-T1, syn-T1, and DL+DiReCT outputs, whereas subcortical volume estimates were more coherent. Dice coefficients revealed an acceptable spatial similarity between the cortices of the 3D-T1 scans and the other images overall, and was higher in the subcortical structures. Intraclass correlation coefficients were consistently lowest when metrics were computed for model-derived inputs, and estimates of thickness were less similar to the ground truth than those of volume. For the people with epilepsy, the 3D-T1 scans showed significant surface deflations across various subcortical structures when compared to healthy controls. Analysis of the 2D-T1 scans enabled the reliable detection of a subset of subcortical abnormalities, whereas analyses of the res-T1 and syn-T1 images were more prone to false-positive results. Conclusions: Resampling and ML image synthesis methods do not currently attenuate partial volume effects resulting from low through plane resolution in anisotropic MRI scans, instead quantitative analyses using 2D-T1 scans should be interpreted with caution, and researchers should consider the potential implications of preprocessing. The recon-all-clinical pipeline is promising, but requires further evaluation, especially when considered as an alternative to the classical pipeline. Key Points: Surface deviations indicative of regional atrophy and hypertrophy were identified in people with idiopathic generalised epilepsy. Partial volume effects are likely to attenuate subtle morphometric abnormalities, increasing the likelihood of erroneous inference. Priors in synthetic image creation models may render them insensitive to subtle biomarkers. Resampling and machine-learning based image synthesis are not currently replacements for research quality acquisitions in quantitative MRI research. The results of studies using synthetic images should be interpreted in a separate context to those using untransformed data.
Open AccessMachine Learning-Based Reconstruction of 2D MRI for Quantitative Morphometry in Epilepsy
Introduction: Structural neuroimaging analyses require ‘research quality’ images, acquired with costly MRI acquisitions. Isotropic (3D-T1) images are desirable for quantitative analyses, however a routine compromise in the clinical setting is to acquire anisotropic (2D-T1) analogues for qualitative visual inspection. ML (Machine learning-based) software have shown promise in addressing some of the limitations of 2D-T1 scans in research applications, yet their efficacy in quantitative research is generally poorly understood. Pathology-related abnormalities of the subcortical structures have previously been identified in idiopathic generalised epilepsy (IGE), which have been overlooked based on visual inspection, through the use of quantitative morphometric analyses. As such, IGE biomarkers present a suitable model in which to evaluate the applicability of image preprocessing methods. This study therefore explores subcortical structural biomarkers of IGE, first in our ‘silver standard’ 3D-T1 scans, then in 2D-T1 scans that were either untransformed, resampled using a classical interpolation approach, or synthesised with a resolution and contrast agnostic ML model (the latter of which is compared to a separate model). Methods: 2D-T1 and 3D-T1 MRI scans were acquired during the same scanning session for 33 individuals with drug-responsive IGE (age mean 32.16 ± SD = 14.20, male n = 14) and 42 individuals with drug-resistant IGE (31.76 ± 11.12, 17), all diagnosed at the Walton Centre NHS Foundation Trust Liverpool, alongside 39 age- and sex-matched healthy controls (32.32 ± 8.65, 16). The untransformed 2D-T1 scans were resampled into isotropic images using NiBabel (res-T1), and preprocessed into synthetic isotropic images using SynthSR (syn-T1). For the 3D-T1, 2D-T1, res-T1, and syn-T1 images, the recon-all command from FreeSurfer 8.0.0 was used to create parcellations of 174 anatomical regions (equivalent to the 174 regional parcellations provided as part of the DL+DiReCT pipeline), defined by the aseg and Destrieux atlases, and FSL run_first_all was used to segment subcortical surface shapes. The new ML FreeSurfer pipeline, recon-all-clinical , was also tested in the 2D-T1, 3D-T1, and res-T1 images. As a model comparison for SynthSR, the DL+DiReCT pipeline was used to provide segmentations of the 2D-T1 and res-T1 images, including estimates of regional volume and thickness. Spatial overlap and intraclass correlations between the morphometrics of the eight resulting parcellations were first determined, then subcortical surface shape abnormalities associated with IGE were identified by comparing the FSL run_first_all outputs of patients with controls. Results: When standardised to the metrics derived from the 3D-T1 scans, cortical volume and thickness estimates trended lower for the 2D-T1, res-T1, syn-T1, and DL+DiReCT outputs, whereas subcortical volume estimates were more coherent. Dice coefficients revealed an acceptable spatial similarity between the cortices of the 3D-T1 scans and the other images overall, and was higher in the subcortical structures. Intraclass correlation coefficients were consistently lowest when metrics were computed for model-derived inputs, and estimates of thickness were less similar to the ground truth than those of volume. For the people with epilepsy, the 3D-T1 scans showed significant surface deflations across various subcortical structures when compared to healthy controls. Analysis of the 2D-T1 scans enabled the reliable detection of a subset of subcortical abnormalities, whereas analyses of the res-T1 and syn-T1 images were more prone to false-positive results. Conclusions: Resampling and ML image synthesis methods do not currently attenuate partial volume effects resulting from low through plane resolution in anisotropic MRI scans, instead quantitative analyses using 2D-T1 scans should be interpreted with caution, and researchers should consider the potential implications of preprocessing. The recon-all-clinical pipeline is promising, but requires further evaluation, especially when considered as an alternative to the classical pipeline. Key Points: Surface deviations indicative of regional atrophy and hypertrophy were identified in people with idiopathic generalised epilepsy. Partial volume effects are likely to attenuate subtle morphometric abnormalities, increasing the likelihood of erroneous inference. Priors in synthetic image creation models may render them insensitive to subtle biomarkers. Resampling and machine-learning based image synthesis are not currently replacements for research quality acquisitions in quantitative MRI research. The results of studies using synthetic images should be interpreted in a separate context to those using untransformed data.
- Open Access
Clinical prediction models for treatment outcomes in newly diagnosed epilepsy: A systematic review
Up to 35% of individuals diagnosed with epilepsy continue to have seizures despite treatment, commonly referred to as drug‐resistant epilepsy. Uncontrolled seizures can directly, or indirectly, negatively impact an individual's quality of life. To inform clinical management and life decisions, it is important to be able to predict the likelihood of seizure control. Those likely to achieve seizure control will be able to return sooner to their usual work and leisure activities and require less follow‐up, whereas those with a poor prognosis will need more frequent clinical attendance and earlier consideration of epilepsy surgery. This is a systematic review aimed at identifying demographic, clinical, physiological (e.g., electroencephalographic), and imaging (e.g., magnetic resonance imaging) factors that may be predictive of treatment outcomes in patients with newly diagnosed epilepsy (NDE). MEDLINE and Embase were searched for prediction models of treatment outcomes in patients with NDE. Study characteristics were extracted and subjected to assessment of risk of bias (and applicability concerns) using the PROBAST (Prediction Model Risk of Bias Assessment Tool) tool. Baseline variables associated with treatment outcomes are reported as prognostic factors. After screening, 48 models were identified in 32 studies, which generally scored low for concerns of applicability, but universally scored high for susceptibility to bias. Outcomes reported fit broadly into four categories: drug resistance, short‐term treatment response, seizure remission, and mortality. Prognostic factors were also heterogenous, but the predictors that were commonly significantly associated with outcomes were those related to seizure characteristics/types, epilepsy history, and age at onset. Antiseizure medication response was often included as a baseline variable, potentially obscuring other factor relationships at baseline. Currently, outcome prediction models for NDE demonstrate a high risk of bias. Model development could be improved with a stronger adherence to recommended TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) practices. Furthermore, we outline actionable changes to common practices that are intended to improve the overall quality of prediction model development in NDE.
Open AccessClinical prediction models for treatment outcomes in newly diagnosed epilepsy: A systematic review
Up to 35% of individuals diagnosed with epilepsy continue to have seizures despite treatment, commonly referred to as drug‐resistant epilepsy. Uncontrolled seizures can directly, or indirectly, negatively impact an individual's quality of life. To inform clinical management and life decisions, it is important to be able to predict the likelihood of seizure control. Those likely to achieve seizure control will be able to return sooner to their usual work and leisure activities and require less follow‐up, whereas those with a poor prognosis will need more frequent clinical attendance and earlier consideration of epilepsy surgery. This is a systematic review aimed at identifying demographic, clinical, physiological (e.g., electroencephalographic), and imaging (e.g., magnetic resonance imaging) factors that may be predictive of treatment outcomes in patients with newly diagnosed epilepsy (NDE). MEDLINE and Embase were searched for prediction models of treatment outcomes in patients with NDE. Study characteristics were extracted and subjected to assessment of risk of bias (and applicability concerns) using the PROBAST (Prediction Model Risk of Bias Assessment Tool) tool. Baseline variables associated with treatment outcomes are reported as prognostic factors. After screening, 48 models were identified in 32 studies, which generally scored low for concerns of applicability, but universally scored high for susceptibility to bias. Outcomes reported fit broadly into four categories: drug resistance, short‐term treatment response, seizure remission, and mortality. Prognostic factors were also heterogenous, but the predictors that were commonly significantly associated with outcomes were those related to seizure characteristics/types, epilepsy history, and age at onset. Antiseizure medication response was often included as a baseline variable, potentially obscuring other factor relationships at baseline. Currently, outcome prediction models for NDE demonstrate a high risk of bias. Model development could be improved with a stronger adherence to recommended TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) practices. Furthermore, we outline actionable changes to common practices that are intended to improve the overall quality of prediction model development in NDE.
- Open Access
Clinical Prediction Models for Treatment Outcomes in Newly-diagnosed Epilepsy
Background: Up to 35% of individuals diagnosed with epilepsy proceed to develop pharmacoresistant epilepsy, leading to persistent uncontrolled seizure activity that can directly, or indirectly, significantly degrade an individual’s quality of life. The factors underlying pharmacoresistance are unclear, but it has been hypothesised that repeated ictogenic activity is conducive to the development of a more robust epileptogenic network. To ensure that the most effective treatment choices are made and ictogenic activity is minimised, accurate outcome modelling at the point of diagnosis is key. Objectives: This review therefore aims to identify demographic, clinical, physiological (e.g. EEG), and imaging (e.g. MRI) factors that may be predictive of treatment outcomes in patients with newly diagnosed epilepsy (NDE). Data sources, study eligibility criteria, participants, and interventions: MEDLINE and EMBASE were searched for prediction models of treatment outcomes in patients with newly diagnosed epilepsy and any non-surgical treatment plan. Study appraisal and synthesis methods: Study characteristics were extracted and subjected to assessment of risk of bias (and applicability concerns) using the PROBAST tool. Prognostic factors associated with treatment outcomes are reported. Results: After screening, 48 models were identified in 32 studies, which generally scored low for concerns of applicability, but universally high for susceptibility to bias. Outcomes reported were heterogenous, but fit broadly into four categories: pharmacoresistance, short-term treatment response, seizure remission, and mortality. Prognostic factors were also heterogenous, but the predictors that were commonly significantly associated with outcomes were those related to seizure characteristics (semiology), epilepsy history, and age at onset. ASM response was often included as a prognostic factor, potentially obscuring factor relationships at baseline. Conclusions: Currently, outcome prediction models for NDE demonstrate a high risk of bias. Model development could be improved with a stronger adherence to recommended TRIPOD practices, and by avoiding including response to treatment as a prognostic factor. Implications of key findings: This review identified semiology, epilepsy history, and age at onset as factors associated with treatment outcome prognosis, suggesting that future prediction model studies should focus on these factors in their models. Furthermore, we outline actionable changes to common practices that are intended to improve the overall quality of prediction model development in NDE. Key Points: This paper presents a systematic literature search for treatment outcome prediction models in newly diagnosed epilepsy. The risk of bias in the included models were evaluated using the PROBAST framework, finding a universally high risk level. The relationship between semiology, epilepsy history, and age at onset with seizure remission should be examined in future prediction model studies. To improve the overall quality of prediction model development in NDE, prospective authors are advised to adhere to TRIPOD guidelines, and to avoid including response to treatment as a prognostic variable.
Open AccessClinical Prediction Models for Treatment Outcomes in Newly-diagnosed Epilepsy
Background: Up to 35% of individuals diagnosed with epilepsy proceed to develop pharmacoresistant epilepsy, leading to persistent uncontrolled seizure activity that can directly, or indirectly, significantly degrade an individual’s quality of life. The factors underlying pharmacoresistance are unclear, but it has been hypothesised that repeated ictogenic activity is conducive to the development of a more robust epileptogenic network. To ensure that the most effective treatment choices are made and ictogenic activity is minimised, accurate outcome modelling at the point of diagnosis is key. Objectives: This review therefore aims to identify demographic, clinical, physiological (e.g. EEG), and imaging (e.g. MRI) factors that may be predictive of treatment outcomes in patients with newly diagnosed epilepsy (NDE). Data sources, study eligibility criteria, participants, and interventions: MEDLINE and EMBASE were searched for prediction models of treatment outcomes in patients with newly diagnosed epilepsy and any non-surgical treatment plan. Study appraisal and synthesis methods: Study characteristics were extracted and subjected to assessment of risk of bias (and applicability concerns) using the PROBAST tool. Prognostic factors associated with treatment outcomes are reported. Results: After screening, 48 models were identified in 32 studies, which generally scored low for concerns of applicability, but universally high for susceptibility to bias. Outcomes reported were heterogenous, but fit broadly into four categories: pharmacoresistance, short-term treatment response, seizure remission, and mortality. Prognostic factors were also heterogenous, but the predictors that were commonly significantly associated with outcomes were those related to seizure characteristics (semiology), epilepsy history, and age at onset. ASM response was often included as a prognostic factor, potentially obscuring factor relationships at baseline. Conclusions: Currently, outcome prediction models for NDE demonstrate a high risk of bias. Model development could be improved with a stronger adherence to recommended TRIPOD practices, and by avoiding including response to treatment as a prognostic factor. Implications of key findings: This review identified semiology, epilepsy history, and age at onset as factors associated with treatment outcome prognosis, suggesting that future prediction model studies should focus on these factors in their models. Furthermore, we outline actionable changes to common practices that are intended to improve the overall quality of prediction model development in NDE. Key Points: This paper presents a systematic literature search for treatment outcome prediction models in newly diagnosed epilepsy. The risk of bias in the included models were evaluated using the PROBAST framework, finding a universally high risk level. The relationship between semiology, epilepsy history, and age at onset with seizure remission should be examined in future prediction model studies. To improve the overall quality of prediction model development in NDE, prospective authors are advised to adhere to TRIPOD guidelines, and to avoid including response to treatment as a prognostic variable.
- Open Access
Cognitive phenotype of juvenile absence epilepsy: An investigation of patients and unaffected siblings
Objective: The cognitive profile of juvenile absence epilepsy (JAE) remains largely uncharacterized. This study aimed to: (1) elucidate the neuropsychological profile of JAE; (2) identify familial cognitive traits by investigating unaffected JAE siblings; (3) establish the clinical meaningfulness of JAE‐associated cognitive traits; (4) determine whether cognitive traits across the idiopathic generalized epilepsy (IGE) spectrum are shared or syndrome‐specific, by comparing JAE to juvenile myoclonic epilepsy (JME); and (5) identify relationships between cognitive abilities and clinical characteristics.Methods: We investigated 123 participants—23 patients with JAE, 16 unaffected siblings of JAE patients, 45 healthy controls, and 39 patients with JME—who underwent a comprehensive neuropsychological test battery including measures within four cognitive domains: attention/psychomotor speed, language, memory, and executive function. We correlated clinical measures with cognitive performance data to decode effects of age at onset and duration of epilepsy.Results: Cognitive performance in individuals with JAE was reduced compared to controls across attention/psychomotor speed, language, and executive function domains; those with ongoing seizures additionally showed lower memory scores. Patients with JAE and their unaffected siblings had similar language impairment compared to controls. Individuals with JME had worse response inhibition than those with JAE. Across all patients, those with older age at onset had better attention/psychomotor speed performance.Significance: JAE is associated with wide‐ranging cognitive difficulties that encompass domains reliant on frontal lobe processing, including language, attention, and executive function. JAE siblings share impairment with patients on linguistic measures, indicative of a familial trait. Executive function subdomains may be differentially affected across the IGE spectrum. Cognitive abilities are detrimentally modulated by an early age at seizure onset.
Open AccessCognitive phenotype of juvenile absence epilepsy: An investigation of patients and unaffected siblings
Objective: The cognitive profile of juvenile absence epilepsy (JAE) remains largely uncharacterized. This study aimed to: (1) elucidate the neuropsychological profile of JAE; (2) identify familial cognitive traits by investigating unaffected JAE siblings; (3) establish the clinical meaningfulness of JAE‐associated cognitive traits; (4) determine whether cognitive traits across the idiopathic generalized epilepsy (IGE) spectrum are shared or syndrome‐specific, by comparing JAE to juvenile myoclonic epilepsy (JME); and (5) identify relationships between cognitive abilities and clinical characteristics.Methods: We investigated 123 participants—23 patients with JAE, 16 unaffected siblings of JAE patients, 45 healthy controls, and 39 patients with JME—who underwent a comprehensive neuropsychological test battery including measures within four cognitive domains: attention/psychomotor speed, language, memory, and executive function. We correlated clinical measures with cognitive performance data to decode effects of age at onset and duration of epilepsy.Results: Cognitive performance in individuals with JAE was reduced compared to controls across attention/psychomotor speed, language, and executive function domains; those with ongoing seizures additionally showed lower memory scores. Patients with JAE and their unaffected siblings had similar language impairment compared to controls. Individuals with JME had worse response inhibition than those with JAE. Across all patients, those with older age at onset had better attention/psychomotor speed performance.Significance: JAE is associated with wide‐ranging cognitive difficulties that encompass domains reliant on frontal lobe processing, including language, attention, and executive function. JAE siblings share impairment with patients on linguistic measures, indicative of a familial trait. Executive function subdomains may be differentially affected across the IGE spectrum. Cognitive abilities are detrimentally modulated by an early age at seizure onset.
- Open Access
- 6 April 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 108, 13-23
Neurocysticercosis-related seizures: Imaging biomarkers
- 6 April 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 108, 13-23
Open AccessNeurocysticercosis-related seizures: Imaging biomarkers
- Open Access
Clinical prediction models for treatment outcome in newly-diagnosed epilepsy: Protocol for a systematic review
Epilepsy, characterised by a predisposition towards unprovoked seizures, is one of the most common neurological disorders globally. Whilst 60-70% of individuals diagnosed with epilepsy will gain seizure control through anti-seizure medication, the mechanisms underlying seizure persistence are unclear. Intractability can significantly degrade a patient’s quality of life amongst other things; the use of predictive modelling of epilepsy outcomes in deciding on treatment therefore offers a tangible benefit to the patient. Early indicators of pharmacoresistance may discourage certain treatment options, and save time in what has been indicated to be a critical stage for newly-diagnosed epilepsy. Primarily, this paper aims to evaluate existing predictive models to identify demographic, clinical, physiological (e.g. EEG), and neuroimaging (e.g. MRI) factors that may be predictive of treatment outcomes in newly-diagnosed epilepsy. Two electronic databases, MEDLINE and EMBASE, will be searched with terms related to prognosis in newly-diagnosed epilepsy, and identified studies will be included for review if they have combined at least two demographic, clinical, neuroimaging, and/or physiological factors to predict treatment outcome in people with newly-diagnosed epilepsy. Papers will be screened by two independent reviewers via titles, abstracts and then full text against the inclusion criteria for eligibility. Data will be extracted by reviewers using standardised forms, assessed for risk of bias using the PROBAST tool and synthesised narratively. If considered appropriate the authors will carry out a meta-analysis on the available data. Prospero registration number – CRD42022329936
Open AccessClinical prediction models for treatment outcome in newly-diagnosed epilepsy: Protocol for a systematic review
Epilepsy, characterised by a predisposition towards unprovoked seizures, is one of the most common neurological disorders globally. Whilst 60-70% of individuals diagnosed with epilepsy will gain seizure control through anti-seizure medication, the mechanisms underlying seizure persistence are unclear. Intractability can significantly degrade a patient’s quality of life amongst other things; the use of predictive modelling of epilepsy outcomes in deciding on treatment therefore offers a tangible benefit to the patient. Early indicators of pharmacoresistance may discourage certain treatment options, and save time in what has been indicated to be a critical stage for newly-diagnosed epilepsy. Primarily, this paper aims to evaluate existing predictive models to identify demographic, clinical, physiological (e.g. EEG), and neuroimaging (e.g. MRI) factors that may be predictive of treatment outcomes in newly-diagnosed epilepsy. Two electronic databases, MEDLINE and EMBASE, will be searched with terms related to prognosis in newly-diagnosed epilepsy, and identified studies will be included for review if they have combined at least two demographic, clinical, neuroimaging, and/or physiological factors to predict treatment outcome in people with newly-diagnosed epilepsy. Papers will be screened by two independent reviewers via titles, abstracts and then full text against the inclusion criteria for eligibility. Data will be extracted by reviewers using standardised forms, assessed for risk of bias using the PROBAST tool and synthesised narratively. If considered appropriate the authors will carry out a meta-analysis on the available data. Prospero registration number – CRD42022329936
- Open Access
The cognitive phenotype of juvenile absence epilepsy and its heritability: An investigation of patients and unaffected siblings
Objective The cognitive profile of juvenile absence epilepsy (JAE) remains uncharacterized. This study aimed to: (i) elucidate the neuropsychological profile of JAE; (ii) assess cognitive trait heritability, by investigating unaffected JAE siblings; (iii) determine whether cognitive traits across the idiopathic generalized epilepsy (IGE) spectrum are shared or syndrome-specific, by comparing JAE to JME. Methods We investigated 123 participants with a comprehensive neuropsychological test battery: 23 JAE patients, 16 unaffected siblings of JAE patients, 45 healthy controls, and 39 JME patients. We correlated clinical measures with cognitive performance data to decode effects of age of onset and duration of epilepsy. Results JAE patients performed worse than controls on tests of verbal comprehension, working memory, verbal fluency, psychomotor speed, mental flexibility, and learning. Patients and siblings were similarly impaired on measures of verbal comprehension, phonemic and semantic fluency compared to controls. Receiver operating characteristic curves indicated successful discrimination of JAE patients and siblings from controls via linguistic measures (area under the curve ≥.77, p ≤ .0001). Individuals with JME were more impaired on response inhibition than those with JAE. Across all patients, those with older age at onset had better performance on psychomotor speed and executive function tests. Conclusions JAE is associated with wide-ranging cognitive difficulties that encompass domains reliant on frontal lobe processing, including expressive language, working memory, and executive function. JAE siblings demonstrate shared impairment with patients on linguistic measures, indicative of a familial trait. Executive function subdomains may be differentially affected across the IGE spectrum.
Open AccessThe cognitive phenotype of juvenile absence epilepsy and its heritability: An investigation of patients and unaffected siblings
Objective The cognitive profile of juvenile absence epilepsy (JAE) remains uncharacterized. This study aimed to: (i) elucidate the neuropsychological profile of JAE; (ii) assess cognitive trait heritability, by investigating unaffected JAE siblings; (iii) determine whether cognitive traits across the idiopathic generalized epilepsy (IGE) spectrum are shared or syndrome-specific, by comparing JAE to JME. Methods We investigated 123 participants with a comprehensive neuropsychological test battery: 23 JAE patients, 16 unaffected siblings of JAE patients, 45 healthy controls, and 39 JME patients. We correlated clinical measures with cognitive performance data to decode effects of age of onset and duration of epilepsy. Results JAE patients performed worse than controls on tests of verbal comprehension, working memory, verbal fluency, psychomotor speed, mental flexibility, and learning. Patients and siblings were similarly impaired on measures of verbal comprehension, phonemic and semantic fluency compared to controls. Receiver operating characteristic curves indicated successful discrimination of JAE patients and siblings from controls via linguistic measures (area under the curve ≥.77, p ≤ .0001). Individuals with JME were more impaired on response inhibition than those with JAE. Across all patients, those with older age at onset had better performance on psychomotor speed and executive function tests. Conclusions JAE is associated with wide-ranging cognitive difficulties that encompass domains reliant on frontal lobe processing, including expressive language, working memory, and executive function. JAE siblings demonstrate shared impairment with patients on linguistic measures, indicative of a familial trait. Executive function subdomains may be differentially affected across the IGE spectrum.